In the first human trial of ATG-101, Australia’s first patient administered – QNT Press Release

[ad_1]

Shanghai and Hongkong, December 19, 2021 /PRNewswire/ – Antengene Corporation Limited (“Antengene”, HKEx code: 6996.HK), a leading innovative global biopharmaceutical company dedicated to the discovery, development and commercialization of hematology and/or hematology First-rate and/or first-rate therapies in the field.Oncology, today announced in Australia The first subject in the Phase I PROBE trial, this is the first human study of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL). The main purpose of this study is to evaluate the safety and tolerability of ATG-101, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of ATG-101; the second purpose is to evaluate ATG -101 preliminary anti-tumor activity.

ATG-101 is a new type of bispecific antibody designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thereby activating anti-tumor immune effectors while providing enhanced Anti-tumor activity, with improved safety. ATG-101 has shown significant anti-tumor activity in animal models of drug-resistant tumors and animal models of anti-PD-1/L1 treatment progress. In addition, in the GLP toxicology study of cynomolgus monkeys, no liver toxicity was observed when the dose was as high as 100 mg/kg.

“ATG-101 is specifically designed to combine the proven PD-1 inhibitory activity with the immunostimulatory activity of 4-1BB. Our goal is to further enhance the effect of immuno-oncology drugs by turning “cold” tumors “hot”” Thereby improving the results of patients who do not respond to anti-PD-1/PD-L1 monotherapy, or re-controlling diseases that are resistant or refractory to these drugs. This has become a growing…

The full story can be found on Benzinga.com

[ad_2]

Source link

Recommended For You

About the Author: News Center